Experience

Tourmaline Bio Enters Into Agreement to be Acquired by Novartis

September 9, 2025

Read more

Related contacts

Bill Sorabella
Partner, New York
Brandon W. Fenn
Partner, New York
Natalie D. Vernon
Associate, Colorado
Sangitha Palaniappa
Associate, Palo Alto
Katherine Denby
Special Counsel, Washington, DC
Pengli Li
Associate, Boston
Nyron J. Persaud
Partner, New York
Megan Browdie
Partner, Washington, DC
Anne Luquette
Associate, San Francisco
Brittany Sanok
Associate, New York
Annie Froehlich
Partner, Washington, DC
Stephanie Gentile
Partner, New York
Austin Holt
Partner, Santa Monica
Christopher Kimball
Partner, Washington, DC
Eileen Marshall
Partner, Washington, DC
Carly Mitchell
Partner, Washington, DC
Phil Mitchell
Partner, New York
Ryan Montgomery
Partner, Boston
John Paul Oleksiuk
Partner, New York
Alan W. Tamarelli
Partner, New York
Dr. Michael Tuscan
Partner, Washington, DC
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Andrew Epstein
Special Counsel, Seattle
J. Brian Stalter
Special Counsel, New York

Related Practices & Industries

Araris Biotech’s up to $1.14 Billion Acquisition by Taiho Pharmaceutical

March 17, 2025

Cooley advised Araris Biotech, a Swiss biotechnology company developing next-generation antibody-drug conjugates, on its definitive agreement to be acquired by Japan-based Taiho Pharmaceutical for up to $1.14 billion in cash.

Read more

Related contacts

Bill Roegge
Partner, New York
Kenneth Krisko
Partner, Reston
Simon Amies
Partner, London
Rita Sobral
Special Counsel, London
Stephanie Parker Palmer
Special Counsel, Reston
Michael Bergmann
Partner, Washington, DC
Brandon W. Fenn
Partner, New York
Eileen Marshall
Partner, Washington, DC
Jeremy Morrison
Partner, Washington, DC
Stella Sarma
Partner, Brussels
Ryan Vann
Partner, Chicago
Natasha Leskovsek
Of Counsel, Washington, DC
Matthew Choy
Associate, New York
Kyle Hess
Associate, New York
Katie Kaufman
Associate, Boston
Edward (Teddy) Nimetz
Associate, New York
Alexandra Paterson
Associate, London
Joseph Perry
Associate, Reston

Related Practices & Industries

Enavate Sciences Co-Leads Normunity’s $75 Million Series B

January 13, 2025

Cooley advised Enavate Sciences, a top investment firm, as the co-lead investor in the $75 million Series B financing round of Normunity, a biotechnology company creating novel anticancer therapies. Lawyers Marc Recht, Brandon Fenn and Barry Kuang led the Cooley team advising Enavate Sciences.

Related contacts

Marc Recht
Partner, Boston
Brandon W. Fenn
Partner, New York
Barry Kuang
Associate, Boston
Liz Gold
Associate, New York
Stephanie Gentile
Partner, New York

Related Practices & Industries

Windward Bio Closes $200 Million Series A

January 10, 2025

Cooley advised Windward Bio, a clinical-stage drug development company committed to improving outcomes for people living with advanced immunological diseases, on its $200 million Series A financing round. Partners Brandon Fenn and Ryan Sansom led the Cooley team advising Windward Bio.

Related contacts

Brandon W. Fenn
Partner, New York
Ryan Sansom
Partner, Boston
Alex Abelson
Associate, New York

Related Practices & Industries

Enavate Sciences Invests in Aviceda Therapeutics $207.5 Million Series C

January 7, 2025

Cooley advised Enavate Sciences, a top investment firm, on its participation in the $207.5 million Series C financing round of Aviceda Therapeutics, a clinical-stage biotech company focused on developing next-generation immunomodulators. Lawyers Marc Recht, Brandon Fenn and Barry Kuang led the Cooley team advising Enavate Sciences.

Related contacts

Marc Recht
Partner, Boston
Brandon W. Fenn
Partner, New York
Barry Kuang
Associate, Boston

Related Practices & Industries

View more

Admissions and credentials

New York